Prescription Weight Loss Injections UK: Complete 2026 Guide

Prescription weight loss injections — sometimes called "slimming jabs" in the popular press — are prescription-only medications delivered via subcutaneous injection that help people lose a significant amount of body weight. They belong to a class of drugs called GLP-1 receptor agonists (and, in the case of tirzepatide, dual GIP/GLP-1 receptor agonists).

These medications work by mimicking the body's natural incretin hormones, which are released after eating. They act on receptors in the brain to reduce appetite and increase feelings of fullness, while also slowing gastric emptying so food stays in the stomach longer. The result is that patients naturally eat less without the constant hunger that undermines most conventional diets.

In the UK, three weight loss injections currently hold marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA):

• •Wegovy (semaglutide 2.4 mg) — manufactured by Novo Nordisk
• •Mounjaro (tirzepatide) — manufactured by Eli Lilly
• •Saxenda (liraglutide 3.0 mg) — manufactured by Novo Nordisk

All three are prescription-only medicines (POMs), meaning you cannot legally buy them over the counter or without a valid prescription from a registered prescriber.

Wegovy is the weight-management formulation of semaglutide, the same active ingredient found in the diabetes medication Ozempic (though at a higher dose). It received MHRA approval for weight management in the UK in 2022 and was recommended by NICE (Technology Appraisal TA875) in 2023.

How it works: Semaglutide is a GLP-1 receptor agonist that reduces appetite by acting on brain centres involved in hunger regulation. It is injected once weekly using a pre-filled pen device.

Dosing schedule: Wegovy uses a gradual dose-escalation over 16 weeks: - Weeks 1–4: 0.25 mg weekly - Weeks 5–8: 0.5 mg weekly - Weeks 9–12: 1.0 mg weekly - Weeks 13–16: 1.7 mg weekly - Week 17 onwards: 2.4 mg weekly (maintenance dose)

Clinical efficacy: In the pivotal STEP trials, participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. Some patients lost over 20% of their starting weight.

UK supply situation (2026): Wegovy has experienced intermittent supply constraints since its UK launch due to extraordinarily high global demand. As of early 2026, supply has improved considerably, though some pharmacies may still experience occasional stock issues. Novo Nordisk has expanded manufacturing capacity, including a new production facility, to address demand.

Common side effects: Nausea (particularly during dose escalation), vomiting, diarrhoea, constipation, and abdominal pain. These are typically mild to moderate and tend to improve as the body adjusts to each dose level.

Mounjaro (tirzepatide) received MHRA approval for type 2 diabetes and was subsequently approved for weight management. It represents a new class of medication — a dual GIP/GLP-1 receptor agonist — that acts on two incretin pathways simultaneously.

How it works: Tirzepatide activates both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor. This dual mechanism appears to produce greater weight loss than GLP-1 agonists alone, as GIP receptor activation provides additional metabolic benefits including enhanced fat metabolism and improved insulin sensitivity.

Dosing: Mounjaro is injected once weekly, with dose escalation from 2.5 mg up to a maximum of 15 mg. The standard titration schedule increases the dose every 4 weeks.

Clinical efficacy: In the SURMOUNT-1 trial, participants on tirzepatide 15 mg lost an average of 22.5% of body weight over 72 weeks — the highest weight loss seen in any pivotal pharmaceutical trial. Even the lowest dose (5 mg) produced an average of 15% weight loss.

NICE appraisal: NICE has appraised tirzepatide for both type 2 diabetes and weight management. The weight management recommendation follows a similar framework to Wegovy, requiring a BMI of 30 kg/m² or above (or 27+ with weight-related comorbidities).

Private pricing: Mounjaro is available through private clinics at approximately £150–280 per month, depending on the dose and the clinic. Some online pharmacies offer competitive pricing through registered prescribers.

Key advantage: The superior weight loss outcomes have made Mounjaro a popular choice for patients seeking maximum efficacy, though individual responses vary and some patients may respond better to semaglutide.

Saxenda was the first GLP-1 receptor agonist to receive MHRA approval specifically for weight management and has been available in the UK longer than either Wegovy or Mounjaro. While newer options have somewhat overshadowed it, Saxenda remains a valid choice — particularly for patients who do not tolerate semaglutide or tirzepatide.

How it works: Liraglutide is a GLP-1 receptor agonist, but unlike semaglutide, it requires daily injections rather than weekly. It works through the same appetite-suppressing mechanism but has a shorter half-life.

Dosing: Saxenda is injected once daily, with dose escalation over 5 weeks from 0.6 mg to the maintenance dose of 3.0 mg.

Clinical efficacy: In the SCALE trials, participants on liraglutide 3.0 mg lost an average of 8% of body weight over 56 weeks, compared to 2.6% with placebo. While this is less than semaglutide or tirzepatide, it still represents clinically meaningful weight loss.

Advantages: - Longer track record of safety data (available since 2017 in the UK) - More consistent supply — fewer shortage issues than Wegovy - Some patients experience fewer GI side effects than with semaglutide

Disadvantages: - Daily injection rather than weekly - Less weight loss on average compared to newer alternatives - Still relatively expensive privately (approximately £180–250 per month)

NICE guidance: NICE recommended Saxenda (TA664) for adults with a BMI of 35 kg/m² or above (or 32.5+ for certain ethnic groups) who also have pre-diabetes, subject to specialist weight management service oversight. The criteria are somewhat more restrictive than for Wegovy.

Getting weight loss injections through the NHS is possible, but the pathway involves specific eligibility criteria and, in most cases, a wait. The NHS does not prescribe these medications simply because a patient wants to lose weight — they are reserved for people with clinically significant obesity and related health risks.

General NICE criteria for GLP-1 weight management (Wegovy/Mounjaro): - BMI of 30 kg/m² or above, or - BMI of 27 kg/m² or above with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnoea, cardiovascular disease, etc.) - For people of South Asian, Chinese, or other ethnic backgrounds at higher metabolic risk, thresholds are typically lowered by 2.5 kg/m² - Must be prescribed as part of a specialist weight management service (Tier 3 or above) - A maximum treatment duration of 2 years is specified in NICE guidance, after which the patient is reassessed

The typical NHS pathway: 1. GP consultation — discuss weight concerns and establish BMI/comorbidity status 2. Lifestyle interventions — the NHS typically requires evidence that diet and exercise have been attempted 3. Tier 3 referral — referral to a specialist weight management service (waiting times vary enormously by area — from weeks to over a year) 4. Specialist assessment — the weight management team assesses suitability for pharmacotherapy 5. Prescription initiation — if appropriate, medication is started with monitoring

Prescription costs: If you receive these medications on NHS prescription, you pay the standard NHS prescription charge of £9.90 per item in England (as of 2026). Prescriptions are free in Scotland, Wales, and Northern Ireland, and patients with certain exemptions (including those with diabetes) may receive free prescriptions in England.

Important caveat: Not all NHS areas have equal access to Tier 3 weight management services. There is significant regional variation — a so-called "postcode lottery" — which means waiting times and availability differ substantially across the country.

For those who do not meet NHS criteria or who do not wish to wait for NHS referral, private clinics offer an alternative route to prescription weight loss injections. The private market for these medications has expanded rapidly in the UK since 2023.

How the private pathway works: 1. Online or in-person consultation — a registered prescriber (doctor, nurse prescriber, or pharmacist prescriber) assesses your medical history, BMI, and suitability 2. Prescription issued — if clinically appropriate, a private prescription is written 3. Medication dispensed — either posted directly from a registered pharmacy or collected from a local pharmacy

Typical private costs (2026): - Consultation fee: £0–100 (many online services include this in the medication price) - Wegovy: £200–300 per month at maintenance dose - Mounjaro: £150–280 per month depending on dose - Saxenda: £180–250 per month

Choosing a reputable private clinic: - Ensure the prescriber is registered with the General Medical Council (GMC), General Pharmaceutical Council (GPhC), or Nursing and Midwifery Council (NMC) - The clinic or pharmacy should be registered with the Care Quality Commission (CQC) in England (or equivalent regulators in devolved nations) - Be wary of services that prescribe without a proper medical consultation or that offer medications at suspiciously low prices - Legitimate services will always conduct a medical assessment, check contraindications, and provide follow-up support

Red flags to watch for: - No medical consultation before prescribing - Medications posted from outside the UK without proper importation - Prices significantly below market rate (may indicate counterfeit products) - No regulated pharmacy involved in dispensing - Claims that a prescription is not needed

Telemedicine services: Several MHRA-compliant telemedicine platforms now offer weight loss injection prescriptions following online video or questionnaire-based consultations. These can be convenient but ensure they meet the regulatory standards described above.

Starting weight loss injections involves a period of adjustment. Here is what patients typically experience during the first few months.

Week 1–4 (initiation dose): - Appetite reduction usually begins within the first week, though it may be subtle at the lowest dose - Common side effects include mild nausea, particularly after eating large or fatty meals - Most patients lose 1–3 kg in the first month, primarily through reduced caloric intake - Injection technique is straightforward — the pre-filled pens are designed for self-administration in the abdomen, thigh, or upper arm

Month 2–4 (dose escalation): - As the dose increases, appetite suppression becomes more pronounced - Nausea may temporarily worsen with each dose increase before the body adjusts - Weight loss accelerates, with most patients losing 4–8 kg by month 3–4 - Dietary habits often shift naturally — patients report reduced interest in high-calorie foods

Month 4–6 (approaching maintenance): - Patients reaching maintenance dose typically experience the strongest appetite suppression - Weight loss continues at a steady rate - GI side effects usually stabilise or diminish - Total weight loss of 8–15% of starting weight is common by this stage

Beyond 6 months: - Weight loss continues but gradually slows, typically reaching a plateau at 12–18 months - Lifestyle modifications (diet quality and physical activity) become increasingly important for maximising and maintaining results - Regular follow-up with the prescriber is essential to monitor for side effects and assess continued benefit

Important considerations: - These medications are most effective when combined with dietary changes and increased physical activity — they are not a substitute for lifestyle modification - Weight regain is common if the medication is stopped without sustained lifestyle changes - Not everyone responds equally — approximately 10–15% of patients may be "non-responders" who lose less than 5% of body weight - Ongoing monitoring of blood pressure, blood glucose, and other metabolic markers is recommended

This article is for educational purposes only and does not constitute medical advice. Always consult a registered healthcare professional before starting any prescription medication.